Prime Medicine, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
PRME$3.90-9.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss F-
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Year Ended December 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2025 | 2024 |
| Revenue: | ||
| Collaboration revenue — related party | $4,586 | $1,609 |
| Collaboration revenue | 46 | 1,374 |
| Total revenue | 4,632 | 2,983 |
| Operating expenses: | ||
| Research and development | 160,636 | 155,289 |
| General and administrative | 52,346 | 50,161 |
| Total operating expenses | 212,982 | 205,450 |
| Loss from operations | (208,350) | (202,467) |
| Other income: | ||
| Interest income | 4,149 | 3,522 |
| Accretion (amortization) of investments | 2,479 | 3,507 |
| Change in fair value of short-term investment — related party | 432 | (485) |
| Other income, net | 148 | 41 |
| Total other income, net | 7,208 | 6,585 |
| Net loss attributable to common stockholders | $(201,142) | $(195,882) |
| Net loss per share attributable to common stockholders, basic and diluted | $(1.35) | $(1.65) |
| Weighted-average common shares outstanding, basic and diluted | 148,758,527 | 118,600,381 |
| Comprehensive loss: | ||
| Net loss | $(201,142) | $(195,882) |
| Change in unrealized loss on investments, net of tax | 81 | 16 |
| Comprehensive loss | $(201,061) | $(195,866) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.